scfv-mdec-205-gp100

scfv-mdec-205-gp100 is an engineered fusion protein designed for cancer immunotherapy, specifically targeting the melanoma-associated antigen gp100 to dendritic cells through a single-chain fragment variable (scFv) directed to the dendritic cell-specific receptor DEC-205. This construct enables efficient delivery of the tumor antigen to dendritic cells, promoting antigen presentation on both MHC class I and II molecules, which enhances activation of gp100-specific CD4+ and CD8+ T cells. The mechanism leverages antigen targeting to DEC-205, improving the immune response against tumors expressing gp100. Published results show significant suppression of melanoma growth in preclinical models, and the concept is designed for potential melanoma vaccine applications[1][2][3].

Other names

scfv-mdec-205-gp100scfv-mdec205-gp100scfv-mdec 205-gp100